Table 2 Epidemiologic and economic results
Patients | Pazopanib | Sunitinib | Difference | Percent | |
|---|---|---|---|---|---|
Per patient and cycle pharmacological costs | €4,046 | €4,904 | -€858 | -17.50% | |
Per patient annual (8 cycles) pharmacological costs | €32,365 | €39,232 | -€6,867 | -17.50% | |
Per patient annual costs associated with AE management | €662 | €974 | -€312 | -32.03% | |
Per patient overall annual costs | €33,027 | €40,206 | -€7,179 | -17.85% | |
Year 2013 | |||||
Advanced RCC at diagnosis | 854 | ||||
Progressions to advanced RCC | 934 | ||||
Advanced RCC (favorable or intermediate risk) | 1,591 | ||||
Pharmacological costs | €29,350,968 | €35,578,198 | -€6,227,230 | -17.50% | |
Overall costs | €30,404,210 | €37,127,832 | -€6,723,622 | -18.11% | |
Year 2014 | |||||
Advanced RCC at diagnosis | 866 | ||||
Progressions to advanced RCC | 948 | ||||
Advanced RCC (favorable or intermediate risk) | 1,615 | ||||
Pharmacological costs | €28,925,945 | €35,063,000 | -€6,137,056 | -17.50% | |
Overall costs | €29,963,935 | €36,590,195 | -€6,626,260 | -18.11% | |
Year 2015 | |||||
Advanced RCC at diagnosis | 878 | ||||
Progressions to advanced RCC | 962 | ||||
Advanced RCC (favorable or intermediate risk) | 1,638 | ||||
Pharmacological costs | €28,483,391 | €34,526,553 | -€6,043,162 | -17.50% | |
Overall costs | €29,505,501 | €36,030,382 | -€6,524,881 | -18.11% |